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ABSTRACT
Introduction: Fentanyl iontophoretic
transdermal system (fentanyl ITS, IONSYS) is
a patient-controlled analgesia system used for
the management of acute postoperative pain,
designed to be utilized in a hospital setting. The
objective of the two studies was to determine if
fentanyl ITS could be safely used with X-rays,
computerized tomography (CT) scans and
radiofrequency identification (RFID) devices.
Methods: The ITS system has two components:
controller and drug unit; the studies utilized ITS
systems without fentanyl, referred to as the ITS
Placebo system. The first study evaluated the
effect of X-radiation on the operation of an ITS
Placebo system. Five ITS Placebo systems were
exposed to X-rays (20 and 200 mSv total
radiation dose—the 200 mSv radiation dose
represents a tenfold higher exposure than in
clinical practice) while operating in the Ready
Mode and five were exposed while operating in
the Dose Mode. The second study evaluated the
effect of RFID (worst-case scenario of direct
contact with an RFID transmitter) on the
operation of an ITS Placebo system. During
these tests, observations of the user interface
and measurements of output voltage confirmed
proper function throughout all operational
modes (Ready Mode, Dose Mode, End-of-Use
Mode, and End-of-Life Mode).
Results: The ITS Placebo system met all
specifications and no functional anomalies
were observed during and following X-ray
exposure at two radiation dose levels or
exposure at six different combinations of RFID
frequencies and field strengths.
Conclusion: The performance of the ITS system
was unaffected by X-ray exposure levels well
beyond those associated with diagnostic X-rays
and CT scans, and by exposure to
radiofrequency field strengths typically
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generated by RFID devices. These results provide
added confidence to clinicians that the fentanyl
ITS system does not need to be removed during
diagnostic X-rays and CT scans and can also be
utilized in close proximity to RFID devices.
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Fentanyl iontophoretic transdermal system (ITS
IONSYS, The Medicines Company, Parsippany,
NJ, USA) is a patient-controlled analgesia (PCA)
system indicated for the short-term
management of acute postoperative pain in
adult patients requiring analgesia [1]. It is
worn by the patient on the chest or upper
outer arm and is self-adhesive. It employs
iontophoresis to deliver fentanyl across intact
skin which then diffuses into the systemic
circulation and is transported to the central
nervous system. When the patient activates a
dose by double-pressing a button, the system
delivers a dose of fentanyl over a period of
10 min [2]. Fentanyl ITS has a well-documented
efficacy and safety profile [3–9]. It has been
shown to be more efficacious than placebo in
three Phase III trials [3–5] and to have similar
efficacy to morphine intravenous (IV) PCA in
four Phase III trials [6–9]. It was approved for use
by the United States (US) Food and Drug
Administration (FDA) on April 30, 2015 and
by the European Commission on November 19,
2015.
The fentanyl ITS system comprises a
controller and a drug unit that are snapped
together by the health-care professional before
being attached to the patient’s chest or upper
outer arm [2]. The fentanyl ITS drug unit
contains no components or materials that
could be affected by diagnostic X-rays,
computerized tomography (CT) scans or
radiofrequency identification (RFID)
transmitters. The fentanyl ITS controller
contains semiconductor components that
could potentially be affected by radiation from
diagnostic X-rays, CT scans or RFID
transmitters. The controller has four primary
modes of operation as described in Table 1. The
fentanyl ITS was tested and verified to be in
compliance with International Electrotechnical
Commission (IEC) 60601-1-2 (Medical electrical
equipment—Part 1–2: General requirements for
basic safety and essential performance-collateral
standard: electromagnetic disturbances—
requirements and tests) at frequencies and
field strength levels for a hospital
environment. All medical devices must meet
this standard to be approved for use. X-rays and
CT scans are commonly utilized in the hospital
setting as are RFID devices. RFID transmitters
are located throughout hospitals including
patient rooms and are utilized to track assets
(e.g., IV PCA pumps) and monitor patients. The
current US prescribing information indicates
that fentanyl ITS should be removed prior to
X-ray or CT scan and also recommends a
separation distance of 2.3 m between fentanyl
ITS and RFID transmitters. In these two studies,
the function of the fentanyl ITS was evaluated
during and after exposure to X-ray and RFID
transmitters to determine whether the
prescribed separation distance and the removal
precautions are necessary.
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MATERIALS AND METHODS
The studies utilized an ITS system without
fentanyl, referred to as the ITS Placebo system.
The ITS controller contains semiconductor
components that could potentially be affected
by radiation from X-rays, CT scans or from
radiofrequency (RF) energy typical of RFID
transmitters. The drug unit was not evaluated
since it does not contain any components or
materials that could be affected by diagnostic
X-rays or RF energy from RFID transmitters. The
controller unit used in the ITS Placebo systems is
identical to the controller unit in fentanyl ITS.
Study 1: Fentanyl ITS and X-Ray Exposure
The objective of the first study was to evaluate
the operational performance of the controller
unit when exposed to X-radiation exceeding
typical ranges for diagnostic X-rays and CT
scans. At the start of the study, the controller
and the placebo drug unit were assembled.
Once assembled, the green light-emitting
diode flashed continuously and the
liquid–crystal display shows 0 for dose count
indicating normal activation of the system. This
mode of operation is defined as the ‘‘Ready
Mode’’. Five ITS Placebo systems were tested in
the Ready Mode and 5 ITS Placebo systems were
tested after dose activation (i.e., the dose button
had been depressed twice within 3 s to initiate a
dose, defined as the ‘‘Dose Mode’’).
The X-ray test equipment was set to 150 kV
and to exposure durations necessary to provide
radiation doses of 20 and 200 mSv. The 20 mSv
dose exceeds the typical range used for both
X-ray and CT scan. The 200 mSv dose greatly
exceeds the typical radiation dose to simulate
multiple exposures or unusual variations in the
CT procedure to ensure that the test conditions
provided a wide margin of safety.
Each ITS Placebo system in the Ready Mode
was connected to a test fixture with a connector
for monitoring the electrical performance of the
controller. Half of the ITS Placebo systems were
activated to enter the Dose Mode. A digital
multimeter was connected to the test fixture to
record the voltage output from the controller
over a 10-min dosing period. System status in
the Ready and Dose Modes was monitored
throughout the test. The controller output
currents were calculated from the voltage
measurements using Ohm’s law. The nominal
target output current of the controller is 170 lA.
Study 2: Fentanyl ITS and RFID Exposure
The objective of the second study was to
determine if the controller unit of the fentanyl
ITS maintains operational performance when
exposed to RFIDs in direct contact with the
Table 1 Description of each mode of operation of the fentanyl ITS
Mode LED LCD Audio Current
output
Ready Mode Slow ﬂashing green Completed dose count None Off
Dose Mode Fast ﬂashing green Completed dose count/progress indicator Single long tone Enabled
End-of-Use Mode Off Flashing completed dose count None Off
End-of-Life Mode Flashing red Completed dose count Repeated short tones Off
ITS iontophoretic transdermal system, LCD liquid-crystal display, LED light-emitting diode
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controller. While RFID devices are typically
positioned at some distance from the patient,
direct contact enabled testing of a ‘‘worst-case’’
scenario to fully evaluate safety.
The tests were performed using a set of
International Organization for Standardization
(ISO) and IEC standards that had previously
been developed with AIM Healthcare Initiative
and the US FDA [10].
The following frequencies and field strengths
representative of RFIDs were tested in direct
contact with three ITS Placebo systems:
134.2 kHz at 65 A/m (ISO 14223). 13.56 MHz
at 7.5 A/m (IEC 14443 Type A), 13.56 MHz at
7.5 A/m (IEC 14443 Type B), 13.56 MHz at 5 A/
m (IEC 15693), 900 MHz at 54 V/m (IEC
18000-6 Type C) and 2.45 GHz at 54 V/m (IEC
18000-4 Mode 1).
The controller and the placebo drug unit
were assembled. Each ITS Placebo system in the
Ready Mode was then connected to a test fixture
with a connector for monitoring electrical
performance of the controller. Half of the ITS
Placebo systems were activated to enter the
Dose Mode. A digital multimeter was connected
to the test fixture to record the voltage output
from the controller over the 10 min dosing
period. System status in the Ready and Dose
Modes was monitored throughout the test. The
controller output currents were calculated from
the voltage measurements using Ohm’s law.
System Performance Testing
System performance tests were performed on the
ITSPlacebo systemsafter exposure toX-ray andRF
radiation. The ITS Placebo systems were checked
to determine if theywould continue to operate in
the Ready and Dose Modes, and automatically
transition to the End-of-Use and End-of-Life
modes. The controller was designed to operate
for 24 h and then enter the End-of-Use Mode;
therefore, tests were completed after 24 h,
including elapsed time and dose count. The
controller was also designed to display the
number of doses delivered for 12 h beyond the
24 h use period and then enter the End-of-Life
Mode. End-of-Life tests included elapsed time and
dose count.
System performance tests included
determining: (1) if the system delivered a dose
only when the dosing button was pressed twice
within 3 s; (2) if the system delivered an output
current less than or equal to the maximum
specified current of 195.5 lA; (3) if the dosing
interval was equal to or less than 11 min; (4) if the
system maintained a dose lockout during the
dosing period and (5) if the system provided a
dose count equal to or less than the number of
doses delivered.
Compliance with Ethics Guidelines
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
Study 1: Iontophoretic Transdermal (ITS)
Placebo System and X-Ray Exposure
Duringand following exposure of the ITSPlacebo
system to each X-ray energy level, all
specifications were met and no anomalies were
observed. During X-ray exposure there was no
output current detected in Ready Mode, and in
Dose Mode the output current was in the range
from 169.65 to 171.94 lA (nominal target is
170 lA), which is well within specifications
(Table 2). Following X-ray exposure, the ITS
Placebo systems remained in Ready Mode and
output current was off as expected until the dose
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buttonwas pressed and released twice within 3 s,
when the fentanyl ITS transitioned to Dose
Mode, as specified. During Dose Mode after
X-ray exposure, additional presses of the dose
button had no effect (i.e., the lockout was
functioning properly), and output current was
ina range from169.70 to170.94 lA,which iswell
within specifications (Table 3). As expected, the
ITS Placebo systems automatically transitioned
back to Ready Mode after the specified dose
duration, and the output current returned to
zero. The Placebo ITS systems automatically
transitioned as expected to End-of-Use Mode at
24 h (range 23 h, 57 min to 23 h, 59 min) and
then automatically transitioned to End-of-Life
Mode 12 h later (range 11 h, 57 min to 11 h,
59 min) as expected. As expected, after entering
the End-of-Use and End-of-Life Modes, the
system appropriately remained off (i.e., no
voltage output).
Table 2 ITS placebo system X-radiation test results












1 Ready 20 0 0
200 0 0
2 Ready 20 0 0
200 0 0
3 Ready 20 0 0
200 0 0
4 Ready 20 0 0
200 0 0
5 Ready 20 0 0
200 0 0
6 Dose 20 170.08 171.32
200 169.65 171.19
7 Dose 20 170.57 171.94
200 170.45 171.69
8 Dose 20 170.08 171.32
200 169.65 171.19
9 Dose 20 170.2 171.44
200 170.08 171.32
10 Dose 20 169.65 171.19
200 169.83 171.07
The exposure time to ensure 200 mSv was 17 min 15 s, the Dose Mode time was about 10 min, and at the end of the Dose
Mode the system went back to the Ready Mode for the remaining test time and the voltage recorded was 0 V
ITS iontophoretic transdermal system
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Study 2: Fentanyl ITS and RFIDs
During and following exposure to RF radiation at
all frequencies tested, the Placebo ITS system met
specifications and no anomalies were observed.
During RF exposure, there was no output current
detected in Ready Mode, and in Dose Mode the
output current ranged from 169.74 to 173.66 lA,
which is well within specifications (Table 4). The
ITS Placebo systems automatically transitioned
back to Ready Mode after the specified dose
duration, and the output current returned to zero
as specified (Table 5). The Placebo ITS systems
automatically transitioned to End-of-Use Mode at
the specified 24 h with no output voltage. At this
point, the system appropriately remained off as
expected.
DISCUSSION
Postoperative patients frequently require X-rays
or CT scans. CT scans and radiography work on
the same basic principle: an X-ray beam is
passed through the body where a portion of the
X-rays are either absorbed or scattered by the
internal structures, and the remaining X-ray
pattern is transmitted to a detector (i.e., film or
computer screen) for recording or further
processing by a computer [11]. Common
diagnostic X-ray and CT systems produce
(peak) tube potentials in the range of
25–150 kilovolts (kVp). Evaluations of X-ray
trends (Nationwide Evaluation of X-Ray
Trends) indicate that clinical practice utilizes
peak tube potentials up to 109 kVp for X-ray
and up to 127 kVp for CT scans [12]. Estimates
of the effective dose from diagnostic X-ray are
in the range of 0.02–8 millisievert (mSv).
Estimates of the effective dose from CT scans
are in the range of 2–16 mSv and can vary by a
factor of 10 [13]. The results from this study
indicate that the fentanyl ITS system will
continue to work normally even when
exposed to the level of radiation seen in
X-rays or CT scans and at a level 259 higher
than the typical X-ray and 109 higher than the
typical CT scan. In this study, ITS Placebo
systems performed as expected in the Ready
Table 3 ITS Placebo system performance test results after X-radiation exposure








1 0.000 Pass 169.70 9 min 59 s
2 0.000 Pass 169.95 10 min 0 s
3 0.000 Pass 170.32 10 min 0 s
4 0.000 Pass 170.08 9 min 58 s
5 0.000 Pass 170.94 9 min 59 s
6 0.000 Pass 170.20 9 min 58 s
7 0.000 Pass 170.82 9 min 58 s
8 0.000 Pass 170.20 9 min 59 s
9 0.000 Pass 170.20 9 min 59 s
10 0.000 Pass 169.95 10 min 0 s
ITS iontophoretic transdermal system
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Mode with the dose current off and in the Dose
Mode when the nominal target dose current of
170 lA was administered for 10 min. It is
important to note the ITS continued to
operate as expected even though radiation
exposure was 109 the normal level. These data
support the conclusion that the fentanyl ITS
can be used safely and effectively when exposed
to diagnostic X-rays or CT scans, and therefore
the system does not need to be removed from
patients.
However, as with other radio-opaque
devices, health-care providers do need to
consider placement of the fentanyl ITS and
potential X-rays and CT scans, because while
radiation does not affect the system, it is
radiopaque and therefore could obstruct the
X-ray or CT scan image. For example, if a
patient needs a chest X-ray postoperatively, it
would be advisable to place the system on the
arm; conversely, if the patient has some
reason to need an upper arm or shoulder
X-ray, then the system can be placed on the
chest or the opposite arm. The small system
size and the site placement options for the
system are versatile enough that with some
forethought it should not create an issue with
radiology.
Table 4 ITS Placebo system RFID test results






11 ISO 14223 134.2 kHz at 65 A/m 169.78 172.43
12 ISO 14223 134.2 kHz at 65 A/m 170.62 173.28
13 ISO 14223 134.2 kHz at 65 A/m 169.74 172.42
14 IEC 14443 Type A (13.56 MHz) 7.5 A/m 170.38 172.29
15 IEC 14443 Type A (13.56 MHz) 7.5 A/m 170.91 173.66
16 IEC 14443 Type A (13.56 MHz) 7.5 A/m 170.37 172.99
17 IEC 14443 Type B (13.56 MHz) 7.5 A/m 169.87 172.55
18 IEC 14443 Type B (13.56 MHz) 7.5 A/m 170.01 172.72
19 IEC 14443 Type B (13.56 MHz) 7.5 A/m 170.45 173.21
20 IEC 15693 (13.56 MHz) 5 A/m 170.32 172.94
21 IEC 15693 (13.56 MHz) 5 A/m 170.29 172.99
22 IEC 15693 (13.56 MHz) 5 A/m 170.05 170.19
23 IEC 18000-6 Type C (900 MHz) 54 V/m 170.00 170.14
24 IEC 18000-6 Type C (900 MHz) 54 V/m 169.96 170.08
25 IEC 18000-6 Type C (900 MHz) 54 V/m 170.10 170.22
26 IEC 18000-4 Mode 1 (2.45 GHz) 54 V/m 170.42 172.92
27 IEC 18000-4 Mode 1 (2.45 GHz) 54 V/m 170.60 173.25
28 IEC 18000-4 Mode 1 (2.45 GHz) 54 V/m 170.10 172.26
ITS iontophoretic transdermal system, RFID radiofrequency identiﬁcation, RF radiofrequency
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It is important to note that fentanyl ITS is
not compatible with magnetic resonance
imaging (MRI). Fentanyl ITS contains metal
parts and therefore must be removed and
properly disposed of before an MRI procedure.
Following an MRI procedure, another fentanyl
ITS device can then be applied.
RFID devices are located throughout
hospitals. They are commonly used to track
medications, patients, nurses, doctors, and
equipment in real time. The FDA has set up a
program to work with manufacturers of
potentially susceptible medical devices to test
their products for any adverse effects from RFID
exposures. Therefore, it is critical that any
device (including PCA pumps) be compatible
with RFID devices; the fentanyl ITS system
met all those standards. While the RFID
devices are typically situated at some distance
from a patient, the current study evaluated the
effect of exposure with direct contact to the
controller to encompass the most extreme
possibility. For all test conditions, the system
operated normally in all operating modes
including the Ready or Dose Modes. This is
especially important as the use of RFID devices
in hospitals continues to expand.
It is important to note that this study was
conducted on the second-generation fentanyl
ITS which is the currently marketed system.
Table 5 ITS Placebo system performance test results after RFID exposure








11 0 Pass 169.96 9 min 58 s
12 0 Pass 170.65 9 min 59 s
13 0 Pass 169.79 9 min 58 s
14 0 Pass 170.29 9 min 59 s
15 0 Pass 170.90 10 min 01 s
16 0 Pass 170.54 10 min 01 s
17 0 Pass 169.87 10 min 01 s
18 0 Pass 170.00 9 min 57 s
19 0 Pass 170.49 9 min 59 s
20 0 Pass 170.40 9 min 58 s
21 0 Pass 170.28 9 min 59 s
22 0 Pass 170.16 9 min 59 s
23 0 Pass 170.08 9 min 58 s
24 0 Pass 169.95 9 min 58 s
25 0 Pass 170.20 9 min 59 s
26 0 Pass 170.60 9 min 59 s
27 0 Pass 170.40 10 min 00 s
28 0 Pass 170.16 10 min 00 s
ITS iontophoretic transdermal system, RFID radiofrequency identiﬁcation
1656 Adv Ther (2016) 33:1649–1659
With the first-generation system, it was
determined that the co-packaging of the
electronics within the same primary packaging
as the hydrogels exposed the electronics to
extreme humidity that could potentially
damage the electronics and potentially result
in self-initiation of the system. The challenges
to the first system were unrelated to radiation or
RFID. The second-generation system was
designed to fully address the earlier issues by
separating the hydrogels in the drug unit from
the electronic circuit of the controller during
manufacture and storage, which removed the
primary cause of corrosion and thereby
improved reliability [2].
A limitation of this study was that it was
conducted in the laboratory versus a hospital
setting such that the laboratory data has to be
extrapolated to the clinical setting. The study
was designed to test the system under
conditions that would translate to a hospital
setting. In addition, the study tested extreme
circumstances to demonstrate a large margin of
safety. Specifically, the system was tested with
radiation levels that were 259 higher than the
typical X-ray and 109 higher than the typical
CT scan. For RFID, the system and the RFID
were positioned adjacently, while in the
hospital some distance would exist. It would
not be possible to conduct a study under such
conditions utilizing patients, and overall these
results inform conditions of use in clinical
practice. It is also important to note that this
system has been tested in a comprehensive,
multi-study Phase 3 clinical program that
showed the system to be efficacious with a
safety profile consistent with the administration
of all opioid medications. [3–9] Collectively, the
clinical and laboratory data provide a set of data
that demonstrates the safe and effective use of
the fentanyl ITS system.
CONCLUSION
In conclusion, the results of this study support
the conclusion that the fentanyl ITS can be used
safely and effectively in hospitals utilizing the
RFID technology at any distance. Also, the
fentanyl ITS is not affected by exposure to
radiation levels well beyond those typical of
diagnostic X-rays or CT scans. These results
should provide added confidence to clinicians
that the fentanyl ITS system can be used during
X-rays and CT scans as well as in the proximity
of RFID devices.
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